NEUROD1 and neoplasm: ,40 Compared to other molecular subtype CDXs (14 ASCL1 CDXs, 4 NEUROD1 CDXs, and 4 ATOH1 CDXs), ATOH1 CDXs were the most aggressive, taking only 61 days to reach the target tumor volume of 800–1,000 mm2 compared to ASCL1 (75 days, p = 0.0128) and NEUROD1 (95 days, p < 0.0001) (Figure S1H).